[HTML][HTML] Current treatment options for metastatic head and neck cancer
KAR Price, EE Cohen - Current treatment options in oncology, 2012 - Springer
Opinion statement Head and neck squamous cell carcinoma is now the 8th most common
cancer affecting men in the United States largely due to a rising epidemic of oropharynx …
cancer affecting men in the United States largely due to a rising epidemic of oropharynx …
Head and neck cancer in the elderly population
F Siddiqui, CK Gwede - Seminars in radiation oncology, 2012 - Elsevier
Approximately two-thirds of head and neck cancer (HNC) patients present with
locoregionally advanced stage (III and IV) disease. This requires multimodality therapy …
locoregionally advanced stage (III and IV) disease. This requires multimodality therapy …
Senior adult oncology
A Hurria, IS Browner, HJ Cohen, CS Denlinger… - Journal of the National …, 2012 - jnccn.org
Cancer is the leading cause of death in women and men aged 60 to 79 years. 1 More than
50% of all cancers and more than 70% of cancer-related deaths in the United States occur in …
50% of all cancers and more than 70% of cancer-related deaths in the United States occur in …
Principles of surgical oncology in the elderly
AP Zbar, A Gravitz, RA Audisio - Clinics in geriatric medicine, 2012 - geriatric.theclinics.com
Almost two thirds of all solid tumors are diagnosed in patients over 65 years of age, where
the annual age-adjusted incidence of cancer has shown a slow but steady increase by …
the annual age-adjusted incidence of cancer has shown a slow but steady increase by …
High-dose-rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers
A Bartochowska, M Wierzbicka, J Skowronek… - Brachytherapy, 2012 - Elsevier
PURPOSE: The main purpose of the study was to assess the results of high-dose-rate
brachytherapy (HDRBT) and pulsed-dose-rate brachytherapy (PDRBT) in the palliative …
brachytherapy (HDRBT) and pulsed-dose-rate brachytherapy (PDRBT) in the palliative …
Is age≥ 70 years an important predictor of adverse events among patients enrolled in metastatic melanoma trials? Findings from pooled analyses of therapeutic trials
A Jatoi, JB Allred, VJ Suman, ET Creagan… - Journal of geriatric …, 2012 - Elsevier
BACKGROUND: The current study was undertaken to explore whether older age predicts
adverse event rates in metastatic melanoma patients participating in cancer clinical trials …
adverse event rates in metastatic melanoma patients participating in cancer clinical trials …
Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendations
A Weir, AK Ganti, M deShazo, S Samant… - Journal of Geriatric …, 2012 - Elsevier
In general, the management and reported outcomes for elderly patients with squamous cell
carcinoma of the head and neck (SCCHN) have been similar to those of younger patients …
carcinoma of the head and neck (SCCHN) have been similar to those of younger patients …
Cisplatin und Carboplatin für die palliative Chemotherapie beim metastasierten malignen Melanom
VB Gabriel - 2012 - refubium.fu-berlin.de
Trotz Therapie haben Patienten mit Melanom im Stadium IV nur eine mittlere Überlebenszeit
von etwa acht bis zehn Monaten. Das Ein-Jahres-Überleben beträgt nur 25%. Wir …
von etwa acht bis zehn Monaten. Das Ein-Jahres-Überleben beträgt nur 25%. Wir …